Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

532 ARTÍCULOS , VIENDO DEL 16 AL 30

Lipid lowering and Alzheimer disease risk: A mendelian randomization study

Williams DM, Finan C, Schmidt AF, Burgess S, Hingorani AD.

Ann Neurol. 2020 Jan;87(1):30-39. doi: 10.1002/ana.25642.

Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial

Howard R, Zubko O, Bradley R, Harper E, Pank L, O'Brien J, Fox C, Tabet N, Livingston G, Bentham P, McShane R, Burns A, Ritchie C, Reeves S, Lovestone S, Ballard C, Noble W, Nilforooshan R, Wilcock G, Gray R; Minocycline in Alzheimer Disease Efficacy (MADE) Trialist Group.

JAMA Neurol. 2020 Feb 1;77(2):164-174. doi: 10.1001/jamaneurol.2019.3762.

Pragmatic Trials and Repurposed Drugs for Alzheimer Disease

Schneider LS.

JAMA Neurol. 2020 Feb 1;77(2):162-163. doi: 10.1001/jamaneurol.2019.3784.

Alzheimer's Disease Targeted Nano-Based Drug Delivery Systems

Altinoglu G, Adali T.

Curr Drug Targets. 2020;21(7):628-646. doi: 10.2174/1389450120666191118123151.

A disease-modifying treatment for Alzheimer's disease: focus on the trans-sulfuration pathway

Berry T, Abohamza E, Moustafa AA.

Rev Neurosci. 2020 Apr 28;31(3):319-334. doi: 10.1515/revneuro-2019-0076.

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials

Wessels AM, Tariot PN, Zimmer JA, Selzler KJ, Bragg SM, Andersen SW, Landry J, Krull JH, Downing AM, Willis BA, Shcherbinin S, Mullen J, Barker P, Schumi J, Shering C, Matthews BR, Stern RA, Vellas B, Cohen S, MacSweeney E, Boada M, Sims JR.

JAMA Neurol. 2020 Feb 1;77(2):199-209. doi: 10.1001/jamaneurol.2019.3988.

Nanotechnology to improve the Alzheimer's disease therapy with natural compounds

Ramalho MJ, Andrade S, Loureiro JA, do Carmo Pereira M.

Drug Deliv Transl Res. 2020 Apr;10(2):380-402. doi: 10.1007/s13346-019-00694-3.

Progress in Target Drug Molecules for Alzheimer's Disease

Xie J, Liang R, Wang Y, Huang J, Cao X, Niu B.

Curr Top Med Chem. 2020;20(1):4-36. doi: 10.2174/1568026619666191203113745.

Mitochondrial dysfunction and Alzheimer's disease: prospects for therapeutic intervention

Lim JW, Lee J, Pae AN.

BMB Rep. 2020 Jan;53(1):47-55. doi: 10.5483/BMBRep.2020.53.1.279.

Mitochondrial Calcium Signaling as a Therapeutic Target for Alzheimer's Disease

Wu AJ, Tong BC, Huang AS, Li M, Cheung KH.

Curr Alzheimer Res. 2020;17(4):329-343. doi: 10.2174/1567205016666191210091302.

The seed of Litchi chinensis fraction ameliorates hippocampal neuronal injury in an Aβ(25-35)-induced Alzheimer's disease rat model via the AKT/GSK-3β pathway

Sun Y, Wu A, Li X, Qin D, Jin B, Liu J, Tang Y, Wu J, Yu C.

Pharm Biol. 2020 Dec;58(1):35-43. doi: 10.1080/13880209.2019.1697298.

A Review of the Brain-Gut-Microbiome Axis and the Potential Role of Microbiota in Alzheimer's Disease

Sun M, Ma K, Wen J, Wang G, Zhang C, Li Q, Bao X, Wang H.

J Alzheimers Dis. 2020;73(3):849-865. doi: 10.3233/JAD-190872.

Potential Therapeutic Approaches to Alzheimer's Disease By Bioinformatics, Cheminformatics And Predicted Adme-Tox Tools

Avram S, Mernea M, Limban C, Borcan F, Chifiriuc C.

Curr Neuropharmacol. 2020;18(8):696-719. doi: 10.2174/1570159X18666191230120053.

Renin-Angiotensin System and Alzheimer's Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives

Ribeiro VT, de Souza LC, Simões E Silva AC.

Protein Pept Lett. 2020;27(6):484-511. doi: 10.2174/0929866527666191230103739.

O-GlcNAcylation as a Therapeutic Target for Alzheimer's Disease

Park J, Lai MKP, Arumugam TV, Jo DG.

Neuromolecular Med. 2020 Jun;22(2):171-193. doi: 10.1007/s12017-019-08584-0. Epub 2020 Jan 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias